Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech
Executive Summary
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
You may also be interested in...
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results
RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.